Author: Jeremiah Momper

1.

Subtherapeutic Meropenem Antibiotic Exposure in Children With Septic Shock Assessed by Noncompartmental Pharmacokinetic Analysis in a Prospective Dataset

Bradley J, Harvey H, Stout D, Momper J, Capparelli E, Avedissian S, et al.

Pediatr Crit Care Med . 2025 Feb; PMID: 39964222

Objectives: To define meropenem plasma concentrations and pharmacodynamic exposure metrics in children with septic shock during the first 3 days of PICU hospitalization. Design: Pharmacokinetic sampling was undertaken in 19...

2.

Acute inflammation upregulates FAHFAs in adipose tissue and in differentiated adipocytes

Ertunc M, Konduri S, Ma Z, Pinto A, Donaldson C, Momper J, et al.

J Biol Chem . 2024 Nov; 300(12):107972. PMID: 39510180

Since the discovery of fatty acid hydroxy fatty acids (FAHFAs), significant progress has been made in understanding their regulation, biochemistry, and physiological activities. Here, we contribute to this understanding by...

3.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, et al.

Alzheimers Res Ther . 2024 Jul; 16(1):151. PMID: 38970127

Background: Amyloid beta protein (Aβ) is a treatment target in Alzheimer's Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small...

4.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease

Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, et al.

medRxiv . 2024 Apr; PMID: 38562783

Background: Amyloid beta protein (Aβ) is a treatment target in Alzheimer's Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen binds to an iron-responsive...

5.

Severe arsenic poisoning due to Ayurvedic supplements

Hardin J, Seltzer J, Suhandynata R, Spiegel B, Silver R, Thomas D, et al.

Clin Case Rep . 2023 Jul; 11(7):e7733. PMID: 37492071

Patients that are taking Ayurvedic supplements have an increased risk of heavy metal toxicity. Lead, arsenic, and mercury are frequently identified in these supplements and can cause clinically significant toxicity....

6.

Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement

Eke A, Olagunju A, Momper J, Penazzato M, Abrams E, Best B, et al.

Clin Pharmacol Ther . 2020 Sep; 110(1):36-48. PMID: 32930408

Information on the extent of drug exposure to mothers and infants during pregnancy and lactation normally becomes available years after regulatory approval of a drug. Clinicians face knowledge gaps on...

7.

Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis

Avedissian S, Skochko S, Le J, Hingtgen S, Harvey H, Capparelli E, et al.

J Pediatr Pharmacol Ther . 2020 Jul; 25(5):413-422. PMID: 32641911

Objectives: The objectives of this study were to 1) define extent and potential clinical impact of increased or decreased renal elimination of meropenem in children with sepsis, based on analysis...

8.

Assessment of ionizable, zwitterionic oximes as reactivating antidotal agents for organophosphate exposure

Taylor P, Yan-Jye S, Momper J, Hou W, Camacho-Hernandez G, Radic Z, et al.

Chem Biol Interact . 2019 May; 308:194-197. PMID: 31100277

Since the development in the 1950's of 2-PAM (Pralidoxime), an antidote that reactivates organophosphate conjugated acetylcholinesterase in target tissues upon pesticide or nerve agent exposure, improvements in antidotal therapy have...